- Details
- Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive variant...
|
- Details
- Zach Klaassen interviews Neal Shore about the EMBARK trial's post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with leuprolide for high-risk biochemical recurrence in prostate cancer patients. Dr. Shore discusses the trial design, key results, and the implications of age stratification ( 70 years) on treatment outcomes and adverse events. The analysis show...
|
- Details
- Zach Klaassen interviews Joaquín Mateo about the ZZ-FIRST trial, which explores the combination of enzalutamide and talazoparib in metastatic hormone-naive prostate cancer. Dr. Mateo discusses the trial design, preliminary results, and the rationale behind combining AR-targeting agents with PARP inhibitors. The study shows promising results in terms of PSA complete response and early indications o...
|
- Details
- Ruchika Talwar interviews David Morris about changes to Medicare Part D resulting from the Inflation Reduction Act. Dr. Morris discusses how these changes benefit prostate cancer patients and other Medicare recipients by reducing out-of-pocket expenses for prescription drugs. Key points include the introduction of a $2,000 annual out-of-pocket maximum cap, the option for cost smoothing to spread p...
|
- Details
- Cédric Pobel discusses an ancillary study of the PEACE-1 trial, focusing on phenotypic and genomic characterization of de novo metastatic prostate cancer. The study analyzes immunohistochemistry and genomic data from patient biopsies. Key findings include the identification of five phenotypes based on androgen receptor and neuroendocrine marker expression. Notably, about 25% of patients show neuro...
|
- Details
- Michael Hofman discusses the development of new criteria for evaluating prostate cancer progression using PSMA PET-CT scans. This work aims to standardize response evaluation and potentially replace the current PCWG3 guidelines that rely on CT and bone scans. Using data from the PRINCE trial, Dr. Hofman's team demonstrates high inter-reader agreement for the new criteria, with almost perfect agree...
|
- Details
- Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the 2024 NCCN prostate cancer guideline updates for systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC). They highlight the new stratification of treatment recommendations based on disease volume and timing of metastases. The discussion covers recent clinical trials supporting triplet therapy for high-volume synchronous disease, inclu...
|
- Details
- Daniel Joyce discusses the financial impact of advanced prostate cancer treatments on patients. He presents research showing significant out-of-pocket costs for oral cancer therapies, particularly for commercially insured patients. Dr. Joyce highlights disparities in costs based on factors like age, race, and income. He emphasizes the importance of addressing financial toxicity in patient care, no...
|
- Details
- Piet Ost discusses the STORM trial, a randomized study comparing stereotactic body radiotherapy (SBRT) with elective nodal radiotherapy (ENRT) in oligometastatic prostate cancer patients. The trial, involving 80% PSMA-PET scanned patients, includes six months of androgen deprivation therapy in both arms. Results show significant benefits for ENRT in biochemical recurrence-free survival and locoreg...
|
